Pulmonx (NASDAQ:LUNG) Receives “Buy” Rating from D. Boral Capital

Pulmonx (NASDAQ:LUNG)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Wells Fargo & Company cut their target price on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Piper Sandler lowered Pulmonx from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $9.00 to $2.50 in a research report on Thursday, July 31st. Lake Street Capital lowered their price objective on Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pulmonx has a consensus rating of “Hold” and a consensus target price of $6.81.

Pulmonx Stock Performance

LUNG stock traded down $0.25 during trading hours on Thursday, reaching $1.72. The stock had a trading volume of 1,566,473 shares, compared to its average volume of 1,015,497. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. Pulmonx has a fifty-two week low of $1.47 and a fifty-two week high of $9.37. The stock has a 50-day simple moving average of $1.72 and a 200 day simple moving average of $2.40. The stock has a market capitalization of $69.89 million, a PE ratio of -1.20 and a beta of 0.44.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. The business had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $20.78 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. Analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Institutional Trading of Pulmonx

Institutional investors have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC grew its stake in shares of Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock valued at $4,118,000 after acquiring an additional 404,022 shares during the period. Trexquant Investment LP lifted its holdings in Pulmonx by 140.0% during the first quarter. Trexquant Investment LP now owns 224,909 shares of the company’s stock valued at $1,514,000 after purchasing an additional 131,209 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Pulmonx by 4.2% in the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock worth $7,720,000 after purchasing an additional 46,116 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of Pulmonx in the first quarter worth approximately $2,041,000. Finally, Legato Capital Management LLC purchased a new stake in shares of Pulmonx in the first quarter worth $606,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.